The primary objective of this multicenter, prospective trial was to determine the safety, efficacy, and cost effectiveness of cefotaxime delivered via an ambulatory delivery system (ADS) in the treatment of patients with a variety of bacterial infections.
The secondary objective was to determine the safety and efficacy of cefotaxime/ADS treatment of infections in a diabetic subgroup.
A total of 238 patients (=18 years) in five infection categories were enrolled from 10 sites.
All patients received cefotaxime/ADS.
Mots-clés Pascal : Bactériose, Infection, Céfotaxime, Antibiotique, Ambulatoire, Coût, Etude multicentrique, Chimiothérapie, Traitement, Homme, Céphalosporine dérivé, Epidémiologie
Mots-clés Pascal anglais : Bacteriosis, Infection, Antibiotic, Ambulatory, Costs, Multicenter study, Chemotherapy, Treatment, Human, Cephalosporin derivatives, Epidemiology
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0668346
Code Inist : 002B02S02. Création : 09/06/1995.